PMID- 21115423
OWN - NLM
STAT- MEDLINE
DCOM- 20110802
LR  - 20230202
IS  - 1938-0666 (Electronic)
IS  - 1526-8209 (Linking)
VI  - 10 Suppl 3
DP  - 2010 Nov
TI  - Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and 
      pathogenesis.
PG  - S59-65
LID - 10.3816/CBC.2010.s.013 [doi]
AB  - The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) 
      pathway mediates multiple cellular functions critical to tumor initiation, 
      progression, and outcomes, including growth and proliferation, metabolism, 
      motility, migration, invasion, angiogenesis, survival, and autophagy. Tight 
      regulation of this pathway is paramount to ensure that multiple cellular inputs 
      are integrated for appropriate cellular outcomes. Frequent deregulation and 
      aberrations of this pathway have been implicated in breast cancer development and 
      progression. This review focuses on the biology of this pathway and its role in 
      breast cancer pathogenesis. The role of therapies directed at targeting mTOR in 
      the PI3K/Akt/mTOR pathway, which are currently being evaluated in clinical 
      trials, will also be reviewed.
FAU - McAuliffe, Priscilla F
AU  - McAuliffe PF
AD  - Departments of Surgical Oncology, The University of Texas, MD Anderson Cancer 
      Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
FAU - Meric-Bernstam, Funda
AU  - Meric-Bernstam F
FAU - Mills, Gordon B
AU  - Mills GB
FAU - Gonzalez-Angulo, Ana M
AU  - Gonzalez-Angulo AM
LA  - eng
GR  - K23 CA121994/CA/NCI NIH HHS/United States
GR  - P50 CA098258/CA/NCI NIH HHS/United States
GR  - T32 CA009599-22/CA/NCI NIH HHS/United States
GR  - 1K23CA121994-01/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Clin Breast Cancer
JT  - Clinical breast cancer
JID - 100898731
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Neoplasm Proteins)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.1.137 (Phosphatidylinositol 3-Kinase)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Antimetabolites, Antineoplastic/therapeutic use
MH  - Breast Neoplasms/drug therapy/*enzymology/etiology/pathology
MH  - Female
MH  - Humans
MH  - Molecular Targeted Therapy/methods
MH  - Neoplasm Proteins/*physiology
MH  - Phosphatidylinositol 3-Kinase/*physiology
MH  - Proto-Oncogene Proteins c-akt/*physiology
MH  - Signal Transduction/drug effects
MH  - TOR Serine-Threonine Kinases/*physiology
EDAT- 2010/12/01 06:00
MHDA- 2011/08/04 06:00
CRDT- 2010/12/01 06:00
PHST- 2010/12/01 06:00 [entrez]
PHST- 2010/12/01 06:00 [pubmed]
PHST- 2011/08/04 06:00 [medline]
AID - C367831404121821 [pii]
AID - 10.3816/CBC.2010.s.013 [doi]
PST - ppublish
SO  - Clin Breast Cancer. 2010 Nov;10 Suppl 3:S59-65. doi: 10.3816/CBC.2010.s.013.